Will RVMD's FY2026 GAAP operating expenses exceed the high end of $1.7B guidance?

FY2025 guidance was revised upward twice ($840-900M initial to $1.03-1.09B), suggesting a pattern of underestimating spending. However, the FY2026 guidance of $1.6-1.7B already reflects a 35-44% step-up and includes $180-200M SBC. Q4 2025 annualized burn of $1.46B is below the midpoint. The key risk is that a positive RASolute 302 readout could accelerate commercial buildout spending, pushing past the $1.7B ceiling. But management typically sets guidance with a buffer.

Biotech companies in the registrational stage commonly exceed initial OpEx guidance by 10-15% as trials expand, sites activate, and manufacturing ramps. RVMD has 8+ registrational trials and 251 open positions. However, the $1.6-1.7B range is already aggressive — management is clearly guiding for high spending. The question is whether they'll exceed even the high end. SBC of $180-200M provides some cushion within GAAP OpEx since it's noncash. Most likely outcome is OpEx falls within the guided range near the high end.

The 8+ registrational trials create cost uncertainty that may not be fully captured in guidance. New trial initiations (RASolute 303, 304, 305, RASolve 301, planned 308, 309) each add incremental costs for site activations, patient recruitment, drug manufacturing, and monitoring. If RASolute 302 reads out positively, management may accelerate RASolute 309 (doublet) and commercial preparations, potentially exceeding the budget. The FY2025 upward revisions suggest management has historically been overly conservative in early guidance.

Management guided $1.6-1.7B knowing exactly what their trial portfolio demands. The wide range ($100M spread) gives them buffer. Q4 2025 was their highest-spend quarter at $364.9M net loss but this includes one-time ramp costs. The steady-state burn for FY2026 should average $400-425M/quarter to hit $1.6-1.7B. Exceeding $1.7B requires sustained quarterly spending above $425M, which is possible but not the base case.

Companies generally set full-year guidance to encompass their spending plans. The $1.7B high end includes SBC of $180-200M. Cash OpEx of ~$1.5B requires ~$375M/quarter. Q4 2025 GAAP OpEx was likely around $365M. Even with ramp-up, staying within $1.7B is achievable with normal execution. The FY2025 revisions were from a much lower initial guide ($840-900M to $1.03-1.09B) — a different dynamic than revising an already-aggressive $1.7B ceiling.

The 251 open positions weighted toward commercialization could drive hiring costs above plan. If they fill these positions at an average fully-loaded cost of $200K-$300K, that's $50M-$75M in incremental annual cost that may not be fully baked into the guidance. Combined with CRO costs for 8+ registrational trials and potential manufacturing scale-up for launch preparation, exceeding $1.7B is plausible. The historical pattern of FY2025 guidance revisions supports this scenario.

Management guided $1.6-1.7B with awareness of their trial portfolio. Most biotech companies stay within or near the high end of annual guidance. The wide range provides buffer. Probability of exceeding is below 50%.

FY2025 showed pattern of upward revisions. The 8+ trials and commercial buildout create upside spending risk. But the $1.7B ceiling is already aggressive. Slight lean toward NO but close to 40%.

Pre-revenue biotechs in registrational phase usually manage to stay near guided spending levels. The guidance was set knowing the trial portfolio. Exceeding the high end requires unexpected acceleration. Less likely than likely.